Cristhiam Mauricio Rojas Hernandez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cristhiam Mauricio Rojas Hernandez has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
- Thein Hlaing Oo
The University of Texas MD Anderson Cancer Center
8 shared publications - Herney Andrés García-Perdomo
UROGIV Research Group, School of Medicine, Universidad del Valle, Cali, Colombia
6 shared publications Wei Qiao
Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, USA
5 shared publications- Ang Li
Section of Hematology-Oncology, Baylor College of Medicine , Houston, TX
4 shared publications - Michael H. Kroll
15Section of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
4 shared publications Partow Kebriaei
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
4 shared publications
Latest Publications
- 14 August 2026
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 49 (8) , 302-306
Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: Clinical Presentation and Outcomes in Three Patients
Immune checkpoint inhibitor therapy has become increasingly recognized as a trigger for hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory syndrome that may lead to organ failure without timely interventions. Given the rarity of this entity, patients are often misdiagnosed with more common oncologic complications. In the present series, we describe 3 patients with diverse clinical pictures evaluated at hospital admissions, who were ultimately diagnosed with immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis. Treatment consisted of dexamethasone combined with an immunosuppressive agent such as anakinra, ruxolitinib, or tocilizumab, with variable clinical responses among patients. These cases highlight the importance of maintaining a high index of suspicion for hemophagocytic lymphohistiocytosis in patients presenting with systemic inflammation during immune checkpoint inhibitor therapy.
- 14 August 2026
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 49 (8) , 302-306
Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: Clinical Presentation and Outcomes in Three Patients
Immune checkpoint inhibitor therapy has become increasingly recognized as a trigger for hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory syndrome that may lead to organ failure without timely interventions. Given the rarity of this entity, patients are often misdiagnosed with more common oncologic complications. In the present series, we describe 3 patients with diverse clinical pictures evaluated at hospital admissions, who were ultimately diagnosed with immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis. Treatment consisted of dexamethasone combined with an immunosuppressive agent such as anakinra, ruxolitinib, or tocilizumab, with variable clinical responses among patients. These cases highlight the importance of maintaining a high index of suspicion for hemophagocytic lymphohistiocytosis in patients presenting with systemic inflammation during immune checkpoint inhibitor therapy.
- Open Access
- 11 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (8)
Risk of venous thromboembolism with CDK 4/6 inhibitor use in breast cancer: A systematic review and meta-analysis.
Hormone receptor-positive (HR+), HER2 negative, non-metastatic breast cancer represents a significant proportion of early-stage breast cancer. The introduction of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors combined with endocrine therapy (ET), have significantly improved disease free survival. Existing studies suggest that CDK 4/6 inhibitors are associated with an increased risk of venous thromboembolism (VTE). We further studied this risk. The databases Medline, Embase, and Cochrane Central Register of Controlled Trials (Central) were searched. 4,624 publications were screened for inclusion, and seven studies were selected for data extraction and analysis. Publications included studied patients who had a diagnosis of non-metastatic breast cancer and received treatment with CKD 4/6 inhibitors. Major exclusion criteria included age <18 years-old, metastatic cancer, and patients already diagnosed with a hypercoagulable disorder. The statistical analysis was performed using RevMan 9.19.0. We reported information in Risk Ratio (RR) and pooled the information with a random-effect meta-analysis according to the heterogeneity expected. We observed the incidence of VTE in the group of patients treated with CDK 4/6 inhibitors to be larger (68/3165) than the incidence of VTE in patients treated with ET alone (11/2205). We found the relative risk of developing VTE was significantly higher with CDK 4/6 inhibitor treatment than with treatment with ET alone (RR 3.8, 95% CI 2.0 to 7.2). Overall, there was not a significant variability in effect estimates from the included studies (I2=0%). As the use of CDK 4/6 grows, this information will help conversations about risks and benefits when selecting treatment plans.
- 11 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (8)
Open AccessRisk of venous thromboembolism with CDK 4/6 inhibitor use in breast cancer: A systematic review and meta-analysis.
Hormone receptor-positive (HR+), HER2 negative, non-metastatic breast cancer represents a significant proportion of early-stage breast cancer. The introduction of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors combined with endocrine therapy (ET), have significantly improved disease free survival. Existing studies suggest that CDK 4/6 inhibitors are associated with an increased risk of venous thromboembolism (VTE). We further studied this risk. The databases Medline, Embase, and Cochrane Central Register of Controlled Trials (Central) were searched. 4,624 publications were screened for inclusion, and seven studies were selected for data extraction and analysis. Publications included studied patients who had a diagnosis of non-metastatic breast cancer and received treatment with CKD 4/6 inhibitors. Major exclusion criteria included age <18 years-old, metastatic cancer, and patients already diagnosed with a hypercoagulable disorder. The statistical analysis was performed using RevMan 9.19.0. We reported information in Risk Ratio (RR) and pooled the information with a random-effect meta-analysis according to the heterogeneity expected. We observed the incidence of VTE in the group of patients treated with CDK 4/6 inhibitors to be larger (68/3165) than the incidence of VTE in patients treated with ET alone (11/2205). We found the relative risk of developing VTE was significantly higher with CDK 4/6 inhibitor treatment than with treatment with ET alone (RR 3.8, 95% CI 2.0 to 7.2). Overall, there was not a significant variability in effect estimates from the included studies (I2=0%). As the use of CDK 4/6 grows, this information will help conversations about risks and benefits when selecting treatment plans.
- Open Access
- 14 May 2026
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (3)
Venous mechanical thrombectomy for deep vein thrombosis in patients with cancer: a single-center prospective study
- 14 May 2026
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (3)
Open AccessVenous mechanical thrombectomy for deep vein thrombosis in patients with cancer: a single-center prospective study
- Open Access
- 6 March 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (5) , 1091-1102
Efficacy and safety of direct oral anticoagulants and low molecular weight heparin for cancer-associated venous thromboembolism in patients with extremes in bodyweight
The purpose of this study is to describe the safety and efficacy of direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) for the treatment of cancer-associated thrombosis in patients with extreme bodyweights. This was a single center, retrospective cohort study of adult patients on therapy for at least 6 months. The primary efficacy outcome of this study was to describe the time to first recurrent venous thromboembolism (VTE) within 6 months, compared between treatment and across weight cohorts. The primary safety objective was to describe the time to first major bleeding (MB) event within 6 months of starting therapy, between treatment types and among the weight groups. Secondary outcomes included incidence of recurrent VTE, MB, clinically relevant non-major bleeding (CRNMB) and the rate of VTE- or bleeding-related mortality. The time to recurrent VTE was comparable between all groups. In the BMI cohort, the time to first MB was 19.5 times longer for DOACs compared to LMWH in the overweight population (p = 0.007) and to first MB or CRNMB was 11.98 times longer (p = < 0.0001). In the weight cohort, the time to first MB or CRNMB was 14.63 times longer for DOACs compared to LMWH in the overweight population (p = 0.011) and 6.41 times longer in the normal weight population (p = 0.0009). There was an insufficient number of patients in the underweight group to perform statistical analysis. The results suggest that in overweight patients, DOACs have similar efficacy and fewer bleeding complications than LMWHs.
- 6 March 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (5) , 1091-1102
Open AccessEfficacy and safety of direct oral anticoagulants and low molecular weight heparin for cancer-associated venous thromboembolism in patients with extremes in bodyweight
The purpose of this study is to describe the safety and efficacy of direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) for the treatment of cancer-associated thrombosis in patients with extreme bodyweights. This was a single center, retrospective cohort study of adult patients on therapy for at least 6 months. The primary efficacy outcome of this study was to describe the time to first recurrent venous thromboembolism (VTE) within 6 months, compared between treatment and across weight cohorts. The primary safety objective was to describe the time to first major bleeding (MB) event within 6 months of starting therapy, between treatment types and among the weight groups. Secondary outcomes included incidence of recurrent VTE, MB, clinically relevant non-major bleeding (CRNMB) and the rate of VTE- or bleeding-related mortality. The time to recurrent VTE was comparable between all groups. In the BMI cohort, the time to first MB was 19.5 times longer for DOACs compared to LMWH in the overweight population (p = 0.007) and to first MB or CRNMB was 11.98 times longer (p = < 0.0001). In the weight cohort, the time to first MB or CRNMB was 14.63 times longer for DOACs compared to LMWH in the overweight population (p = 0.011) and 6.41 times longer in the normal weight population (p = 0.0009). There was an insufficient number of patients in the underweight group to perform statistical analysis. The results suggest that in overweight patients, DOACs have similar efficacy and fewer bleeding complications than LMWHs.
- 5 March 2026
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 32 (4) , 306-313
Primary prophylaxis and treatment of venous thromboembolism in malignancy with focus on lung cancer: a review of current evidence
Purpose of review: Cancer-associated thrombosis (CAT) is a significant cause of mortality in oncology, particularly in lung cancer. The clinical management requires a careful balance between preventing venous thromboembolism (VTE) and minimizing bleeding risks. The aim of this review is to provide the latest evidenced based-approach for primary and secondary prevention of CAT. Recent findings: Results from randomized clinical trials, such as TARGET-TP, CASSINI, and AVERT demonstrated that low-molecular-weight heparin (LMWH) and direct oral anticoagulants (DOACs) reduce VTE incidence in high-risk ambulatory patients (Khorana score ≥2). Lung-cancer-specific data from FRAGMATIC showed that although VTE risk is halved, there is no overall survival benefit, and routine prophylaxis is not recommended for unselected patients, which aligns with current guidelines. For VTE treatment, randomized trials including CARAVAGGIO, SELECT-D, and ADAM VTE showed that DOACs are non-inferior to LMWH with similar major bleeding rates, although some DOACs increase non-major gastrointestinal or genitourinary bleeding. Invasive approaches such as mechanical thrombectomy and catheter-directed thrombolysis remain reserved for life-threatening presentations. Summary: Pharmacotherapy for prevention of CAT in lung cancer must be individualized. DOACs have emerged as a practical and effective alternative to LMWH for both primary and secondary VTE prophylaxis after assessing risk-benefit.
- 5 March 2026
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 32 (4) , 306-313
Primary prophylaxis and treatment of venous thromboembolism in malignancy with focus on lung cancer: a review of current evidence
Purpose of review: Cancer-associated thrombosis (CAT) is a significant cause of mortality in oncology, particularly in lung cancer. The clinical management requires a careful balance between preventing venous thromboembolism (VTE) and minimizing bleeding risks. The aim of this review is to provide the latest evidenced based-approach for primary and secondary prevention of CAT. Recent findings: Results from randomized clinical trials, such as TARGET-TP, CASSINI, and AVERT demonstrated that low-molecular-weight heparin (LMWH) and direct oral anticoagulants (DOACs) reduce VTE incidence in high-risk ambulatory patients (Khorana score ≥2). Lung-cancer-specific data from FRAGMATIC showed that although VTE risk is halved, there is no overall survival benefit, and routine prophylaxis is not recommended for unselected patients, which aligns with current guidelines. For VTE treatment, randomized trials including CARAVAGGIO, SELECT-D, and ADAM VTE showed that DOACs are non-inferior to LMWH with similar major bleeding rates, although some DOACs increase non-major gastrointestinal or genitourinary bleeding. Invasive approaches such as mechanical thrombectomy and catheter-directed thrombolysis remain reserved for life-threatening presentations. Summary: Pharmacotherapy for prevention of CAT in lung cancer must be individualized. DOACs have emerged as a practical and effective alternative to LMWH for both primary and secondary VTE prophylaxis after assessing risk-benefit.
- Open Access
- 23 February 2026
- Published by Springer Nature in Discover Medicine
- Vol. 3 (1) , 15
Clinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab
Background Venous thromboembolism (VTE) is a common cause of morbidity and mortality in patients with multiple myeloma (MM). There has been little evidence investigating the factors associated with VTE during therapy with daratumumab-containing regimens. Objectives Our study examined the association of different clinical, medication- and procedure-related factors on the development of VTE events. Methods We performed a retrospective chart review of multiple myeloma patients treated at our institution with daratumumab-containing regimens and who developed VTE within 12 months of starting daratumumab. We collected the information on clinical factors, cancer therapy, antithrombotic medications, and central venous access procedures during the observation period. A univariate logistic regression was done first to identify variables associated with VTE, after which those variables were entered into a multivariate analysis. Results Among patients with MM who received a daratumumab-containing regimen, the incidence of VTE was 9.6% at 12 months from the initiation of daratumumab. We found that the number of PICC line insertions and the presence of multiple medical comorbidities were associated with VTE development. Conclusions We conclude that VTE is frequent during therapy for MM, particularly in the presence of certain risk factors such as use of multiple PICC line insertions and recent infections. Our observations do not imply causality and limited by the retrospective design, small number of VTE events and lack of time-to-event analysis in the study.
- 23 February 2026
- Published by Springer Nature in Discover Medicine
- Vol. 3 (1) , 15
Open AccessClinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab
Background Venous thromboembolism (VTE) is a common cause of morbidity and mortality in patients with multiple myeloma (MM). There has been little evidence investigating the factors associated with VTE during therapy with daratumumab-containing regimens. Objectives Our study examined the association of different clinical, medication- and procedure-related factors on the development of VTE events. Methods We performed a retrospective chart review of multiple myeloma patients treated at our institution with daratumumab-containing regimens and who developed VTE within 12 months of starting daratumumab. We collected the information on clinical factors, cancer therapy, antithrombotic medications, and central venous access procedures during the observation period. A univariate logistic regression was done first to identify variables associated with VTE, after which those variables were entered into a multivariate analysis. Results Among patients with MM who received a daratumumab-containing regimen, the incidence of VTE was 9.6% at 12 months from the initiation of daratumumab. We found that the number of PICC line insertions and the presence of multiple medical comorbidities were associated with VTE development. Conclusions We conclude that VTE is frequent during therapy for MM, particularly in the presence of certain risk factors such as use of multiple PICC line insertions and recent infections. Our observations do not imply causality and limited by the retrospective design, small number of VTE events and lack of time-to-event analysis in the study.
- Open Access
Venous Thromboembolism in Aggressive B‐Cell Lymphoma Patients Treated with CD19 CAR‐T Therapy: Single‐Institution Study
Background: Large B‐cell lymphomas (LBCLs) are a common subtype of non‐Hodgkin lymphomas. CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy has revolutionized LBCL treatment, with high remission rates but also significant toxicities, including cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS). Venous thromboembolism (VTE) in CAR‐T therapy patients is understudied. Objective: This study aims to determine the incidence and characteristics of acute VTE in LBCL patients treated with CAR‐T therapy and identify baseline clinical features associated with VTE. Methods: We retrospectively reviewed 172 adult LBCL patients treated with CAR‐T therapy from January 2018 to November 2019 at MD Anderson Cancer Center. Data on demographics, clinical characteristics, and adverse events were collected. VTE events within 6 months post‐CAR‐T therapy were confirmed by diagnostic imaging. Statistical analyses included univariate analyses and cumulative incidence functions. Results: The cohort was predominantly male (70%), with a median age of 59 years and advanced‐stage disease (76.16%). The 6‐month incidence of VTE was 7.6%, primarily involving upper extremity events related to central venous catheters. Significant associations were found between VTE and disease histology ( p = 0.033) and high‐grade ICANS ( p = 0.013). PMBCL patients had a higher VTE incidence (30%) compared to DLBCL and TFL. Most VTE events occurred within the first month post‐CAR‐T therapy. Conclusion: LBCL patients receiving CAR‐T therapy have a significant risk of VTE, particularly within the first month and among those with PMBCL and high‐grade ICANS. This highlights the need to study the role of venous thromboprophylaxis in this context.
Open AccessVenous Thromboembolism in Aggressive B‐Cell Lymphoma Patients Treated with CD19 CAR‐T Therapy: Single‐Institution Study
Background: Large B‐cell lymphomas (LBCLs) are a common subtype of non‐Hodgkin lymphomas. CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy has revolutionized LBCL treatment, with high remission rates but also significant toxicities, including cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS). Venous thromboembolism (VTE) in CAR‐T therapy patients is understudied. Objective: This study aims to determine the incidence and characteristics of acute VTE in LBCL patients treated with CAR‐T therapy and identify baseline clinical features associated with VTE. Methods: We retrospectively reviewed 172 adult LBCL patients treated with CAR‐T therapy from January 2018 to November 2019 at MD Anderson Cancer Center. Data on demographics, clinical characteristics, and adverse events were collected. VTE events within 6 months post‐CAR‐T therapy were confirmed by diagnostic imaging. Statistical analyses included univariate analyses and cumulative incidence functions. Results: The cohort was predominantly male (70%), with a median age of 59 years and advanced‐stage disease (76.16%). The 6‐month incidence of VTE was 7.6%, primarily involving upper extremity events related to central venous catheters. Significant associations were found between VTE and disease histology ( p = 0.033) and high‐grade ICANS ( p = 0.013). PMBCL patients had a higher VTE incidence (30%) compared to DLBCL and TFL. Most VTE events occurred within the first month post‐CAR‐T therapy. Conclusion: LBCL patients receiving CAR‐T therapy have a significant risk of VTE, particularly within the first month and among those with PMBCL and high‐grade ICANS. This highlights the need to study the role of venous thromboprophylaxis in this context.
- Open Access
- 28 October 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (1) , 100122
Automated natural language processing to identify venous thromboembolism from diagnostic imaging reports
- 28 October 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (1) , 100122
Open AccessAutomated natural language processing to identify venous thromboembolism from diagnostic imaging reports